Revity (RVTY) Q4 2024: Software Grows 30% as Life Sciences Recovery Remains Uneven
Revity’s fourth quarter highlighted accelerating software momentum and steady diagnostic growth, but life sciences instrumentation and macro uncertainties kept management cautious on 2025. Executives are stepping up strategic investment, banking on normalization in pharma and biotech demand, yet guidance reflects a steady-state recovery with upside only if end-market trends accelerate. Investors should monitor the margin leverage from software, portfolio mix, and the pace of capex normalization in life sciences instruments.
Summary
- Software Outperformance: Signals business delivered standout SaaS and ARR growth, highlighting portfolio shift.
- Diagnostics Stability: Immunodiagnostics and reproductive health continue to anchor growth amid instrument headwinds.
- Prudent Guidance: Management assumes steady recovery, with upside if pharma and biotech rebound accelerates.
Business Overview
Revity is a diversified life sciences and diagnostics company that generates revenue by selling consumables, instruments, software, and services to pharma, biotech, academic, and clinical customers. Its major segments are Life Sciences (including reagents, instruments, and software) and Diagnostics (immunodiagnostics, reproductive health, and applied genomics). The company’s business model blends recurring consumables and software revenue with cyclical instrument sales, creating exposure to both stable and volatile demand pools.
Performance Analysis
Fourth quarter results were defined by broad-based organic growth, with both the life sciences and diagnostics segments exceeding expectations. Software was a clear outperformer, with the Signals business growing more than 30% in the quarter and SaaS annual recurring revenue (ARR) up over 30% for the year, supported by a robust 106% net retention rate. This software momentum is increasingly material, now representing 16% of life sciences revenue and driving margin expansion.
Diagnostics remained a stabilizing force, with immunodiagnostics and reproductive health together comprising the bulk of segment revenue and delivering mid- to high-single-digit growth. Life sciences consumables also posted sequential and year-over-year gains, signaling early signs of normalization in pharma and biotech customer activity. However, instrumentation sales continued to lag, down high single digits in the quarter and low double digits for the year, reflecting ongoing capex constraints in core end markets.
- Software Growth Engine: Signals software drove double-digit portfolio value growth, outpacing the rest of the business and delivering operating leverage.
- Diagnostics Outperformance: Immunodiagnostics grew high single digits for the year, while reproductive health saw a strong finish, led by newborn screening.
- Geographic Variability: China posted high-single-digit growth in Q4, aided by stimulus, but full-year results remain mixed across regions.
Margin expansion was achieved despite modest top-line growth, with adjusted operating margins reaching 30.3% in Q4 and 28.3% for the year. Free cash flow conversion remained robust at 96%, supporting continued share repurchases and strategic flexibility.
Executive Commentary
"In 2024, we made substantial progress towards achieving Revity's full potential. We expect this progress to be even more evident externally once industry demand more fully normalizes, which I believe we are now on a solid path towards as we start 2025."
Prahlad Singh, President and Chief Executive Officer
"We leveraged our strong financial performance and balance sheet position to remain aggressive with our share repurchase activity in the quarter as we were able to buy back another $185 million worth of our shares."
Max Grykowiak, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Software and Digital Expansion
Signals, Revity’s software business, is now a core growth lever, boasting over 30% SaaS ARR growth and a 106% net retention rate. Management is investing further in digital, e-commerce, and AI capabilities, aiming to expand software’s reach into adjacent high-growth markets and drive recurring revenue mix higher.
2. Diagnostics as Growth Anchor
Immunodiagnostics and reproductive health continue to provide a base of stability, with high single-digit and mid-single-digit growth, respectively. The company’s leadership in newborn screening and autoimmune diagnostics supports resilience even as other segments experience volatility.
3. Life Sciences Instruments Lag Recovery
Instrumentation remains a drag, with persistent capex headwinds in pharma and biotech. Management expects only modest improvement in 2025, with normalization tied to broader funding and customer budget cycles. This segment now represents less than 20% of the portfolio, reducing its impact on overall results.
4. Geographic Diversification and China Exposure
China delivered high-single-digit Q4 growth, especially in life sciences, aided by modest stimulus. However, management expects 2025 China growth to align with the overall company, reflecting both opportunity and ongoing policy and pricing risks (notably VBP, or volume-based procurement, in immunodiagnostics).
5. Portfolio Realignment and Segment Reporting
The applied genomics business is being resegmented into life sciences solutions to better align operationally and commercially. This shift consolidates innovation and customer focus, with applied genomics now positioned for recovery after pandemic-driven volatility.
Key Considerations
Revity’s Q4 and 2025 outlook reflect a portfolio in transition, balancing software-driven margin gains against cyclical and macro headwinds in instruments and capex-driven businesses. Management is prioritizing strategic investments while maintaining a conservative stance on demand recovery.
Key Considerations:
- Software Leverage: Signals’ outperformance is driving margin expansion and recurring revenue mix, providing insulation from end-market volatility.
- Diagnostics Momentum: Immunodiagnostics and newborn screening are delivering above-peer growth, anchoring company performance.
- Conservative Guidance Philosophy: Management assumes current demand trends persist, with no acceleration baked into 2025 guidance despite early recovery signals.
- Strategic Investment Step-Up: Increased internal investment is targeted at digital and commercial capabilities, positioning the company for future growth as demand normalizes.
- China and Macro Risks: China is expected to grow in line with the company, but regulatory and pricing headwinds remain a watchpoint.
Risks
Key risks for Revity include the pace and breadth of recovery in pharma and biotech capex, especially for life sciences instruments, as well as ongoing macro, regulatory, and geopolitical uncertainties. FX headwinds, exposure to China’s policy shifts (including VBP), and potential funding volatility in academic and government markets could dampen upside. While software and diagnostics provide ballast, a slower return to normalized demand would limit top-line acceleration and margin upside.
Forward Outlook
For Q1 2025, Revity guided to:
- 3% to 5% organic growth, with steady-state performance expected throughout the year
- Operating margins below full-year average in Q1, ramping in Q4 with volume leverage
For full-year 2025, management maintained guidance:
- 3% to 5% organic growth, 1.5% to 3.5% reported (including FX headwind of 1.5%)
- Adjusted operating margin expansion of 20 to 40 basis points (to 28.5%–28.7%)
- Adjusted EPS of $4.90 to $5.00, with 19% of earnings expected in Q1 due to tax phasing
Management emphasized that guidance assumes no major improvement in end markets, with upside potential if pharma and biotech demand rebounds faster than anticipated. Strategic investments will focus on digital, AI, and commercial expansion, funded by robust cash flow.
- Steady-state recovery is the base case, with upside only if customer budgets accelerate
- Software and diagnostics are expected to continue outperforming other segments
Takeaways
Revity’s Q4 results underscore a business in strategic transition, where software and diagnostics offset cyclical headwinds in instruments. The company’s conservative guidance reflects both prudence and the reality of uneven recovery in core end markets.
- Software and Diagnostics Drive Margin: Signals software and immunodiagnostics are providing both growth and resilience, supporting margin expansion even as instruments lag.
- Portfolio Mix Reduces Volatility: The shift toward recurring software and consumables revenue is dampening exposure to capex cycles, positioning Revity for more stable long-term growth.
- Watch for Recovery Pace: Investors should monitor the timing and breadth of pharma and biotech capex normalization, as well as the impact of stepped-up digital investment on future growth rates.
Conclusion
Revity enters 2025 with software and diagnostics momentum, a more resilient portfolio mix, and a prudent outlook that leaves room for upside if market normalization accelerates. Margin expansion and cash generation remain strengths, but instrument recovery and macro clarity are needed for a return to historical growth rates.
Industry Read-Through
Revity’s results and guidance signal that software and recurring consumables are the most reliable growth engines in the current life sciences and diagnostics landscape. The continued lag in instrument demand is a cautionary read-through for peers with higher capex exposure, while robust performance in diagnostics and software underscores the value of portfolio diversification. China’s stabilization and ongoing policy risks remain a sector-wide watchpoint. The industry’s shift toward digital, AI, and SaaS is accelerating, favoring those with established platforms and recurring revenue bases.